These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 20649841)
1. Proteasome inhibition in medaka brain induces the features of Parkinson's disease. Matsui H; Ito H; Taniguchi Y; Inoue H; Takeda S; Takahashi R J Neurochem; 2010 Oct; 115(1):178-87. PubMed ID: 20649841 [TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. Xie W; Li X; Li C; Zhu W; Jankovic J; Le W J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845 [TBL] [Abstract][Full Text] [Related]
3. A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish. Matsui H; Taniguchi Y; Inoue H; Uemura K; Takeda S; Takahashi R Neurosci Res; 2009 Nov; 65(3):263-71. PubMed ID: 19665499 [TBL] [Abstract][Full Text] [Related]
4. Ammonium chloride and tunicamycin are novel toxins for dopaminergic neurons and induce Parkinson's disease-like phenotypes in medaka fish. Matsui H; Ito H; Taniguchi Y; Takeda S; Takahashi R J Neurochem; 2010 Dec; 115(5):1150-60. PubMed ID: 21219329 [TBL] [Abstract][Full Text] [Related]
5. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. McNaught KS; Perl DP; Brownell AL; Olanow CW Ann Neurol; 2004 Jul; 56(1):149-62. PubMed ID: 15236415 [TBL] [Abstract][Full Text] [Related]
6. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Kordower JH; Kanaan NM; Chu Y; Suresh Babu R; Stansell J; Terpstra BT; Sortwell CE; Steece-Collier K; Collier TJ Ann Neurol; 2006 Aug; 60(2):264-8. PubMed ID: 16862579 [TBL] [Abstract][Full Text] [Related]
7. Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease. Fitzgerald P; Mandel A; Bolton AE; Sullivan AM; Nolan Y Behav Brain Res; 2008 Dec; 195(2):271-4. PubMed ID: 18817814 [TBL] [Abstract][Full Text] [Related]
9. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats. Miwa H; Kubo T; Suzuki A; Kondo T Neurosci Lett; 2006 Jun; 401(1-2):146-9. PubMed ID: 16600504 [TBL] [Abstract][Full Text] [Related]
11. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126 [TBL] [Abstract][Full Text] [Related]
12. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767 [TBL] [Abstract][Full Text] [Related]
13. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Zhu W; Li X; Xie W; Luo F; Kaur D; Andersen JK; Jankovic J; Le W Neurobiol Dis; 2010 Feb; 37(2):307-13. PubMed ID: 19818853 [TBL] [Abstract][Full Text] [Related]
14. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Manning-Boğ AB; Reaney SH; Chou VP; Johnston LC; McCormack AL; Johnston J; Langston JW; Di Monte DA Ann Neurol; 2006 Aug; 60(2):256-60. PubMed ID: 16862576 [TBL] [Abstract][Full Text] [Related]
15. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). Schmidt WJ; Alam M J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541 [TBL] [Abstract][Full Text] [Related]
16. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats. Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250 [TBL] [Abstract][Full Text] [Related]
18. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Pan T; Zhu W; Zhao H; Deng H; Xie W; Jankovic J; Le W Brain Res; 2008 Jul; 1222():222-9. PubMed ID: 18579122 [TBL] [Abstract][Full Text] [Related]
19. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Schapira AH; Cleeter MW; Muddle JR; Workman JM; Cooper JM; King RH Ann Neurol; 2006 Aug; 60(2):253-5. PubMed ID: 16862591 [TBL] [Abstract][Full Text] [Related]
20. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]